Join

Compare · INCR vs NVS

INCR vs NVS

Side-by-side comparison of Intercure Ltd. (INCR) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both INCR and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $274.13B, about 4820.3x INCR ($56.9M).
  • Over the past year, INCR is down 29.8% and NVS is up 22.8% - NVS leads by 52.7 points.
  • NVS has more recent analyst coverage (25 ratings vs 1 for INCR).
PerformanceINCR-29.81%NVS+22.10%
2025-06-04+0.00%2026-06-02
MetricINCRNVS
Company
Intercure Ltd.
Novartis AG
Price
$1.13+6.60%
$143.69+0.15%
Market cap
$56.9M
$274.13B
1M return
+22.83%
-0.64%
1Y return
-29.81%
+22.84%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
News (4w)
0
0
Recent ratings
1
25
INCR

Intercure Ltd.

InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.